Publication:
HLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailand

dc.contributor.authorChonlaphat Sukasemen_US
dc.contributor.authorThawinee Jantararoungtongen_US
dc.contributor.authorParnrat Kuntawongen_US
dc.contributor.authorApichaya Puangpetchen_US
dc.contributor.authorNapatrupron Koomdeeen_US
dc.contributor.authorPatompong Satapornpongen_US
dc.contributor.authorPatcharin Supapsophonen_US
dc.contributor.authorJettanong Klaewsongkramen_US
dc.contributor.authorTicha Rerkpattanapipaten_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherFaculty of Medicine, Ramathibodi Hospital, Mahidol Universityen_US
dc.contributor.otherThai Severe Cutaneous Adverse Drug Reaction (Thai-SCAR) Research Groupen_US
dc.contributor.otherChulalongkorn Universityen_US
dc.date.accessioned2018-12-11T03:34:28Z
dc.date.accessioned2019-03-14T08:02:13Z
dc.date.available2018-12-11T03:34:28Z
dc.date.available2019-03-14T08:02:13Z
dc.date.issued2016-07-18en_US
dc.description.abstract© 2016 Sukasem. Background: The aim of this study was to investigate the predisposition to different types of allopurinol-induced cutaneous adverse drug reactions (CADR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN; SJS-TEN, n = 13), drug reaction with eosinophilia and systemic symptoms (DRESS, n = 10) and Maculopapular eruption (MPE; n = 7), conferred by HLA-B*58:01 in a Thai population.Methods: This case-control association study compares 30 patients with allopurinol-induced CADR, allopurinol-tolerant control patients (n = 100), and a Thai general population (n = 1095). Patients' human leukocyte antigen type B (HLA-B) alleles were genotyped by using a two-stage sequence-specific oligonucleotide probe system.Results: Of a total 30 patients with CADR due to allopurinol, 29 (96.7%) patients were found to be at least heterozygous for HLA-B*58:01, compared to only 4.0% in allopurinol-tolerant patients (p < 0.001). Odds ratio (OR) for the association of HLA-B*58:01 with allopurinol-induced CADR in this population was 696.0 (95% CI: 74.8-6475.0). The HLA-B*58:01 allele was present in all patients with allopurinol-induced SJS-TEN (OR = 579.0, 95%CI: 29.5-11362.7, p < 0.001) and DRESS (OR 430.3, 95%CI: 22.6-8958.9, p < 0.001). Additionally, OR of HLA-B*58:01 was highly significant in the allopurinol-induced MPE patients (OR 144.0, 95%CI: 13.9-1497.0, p < 0.001).Conclusion: In this study we confirmed the association between HLAB*58:01 and allopurinol-induced SJS-TEN in a Thai population. In addition, we identified an association between HLA-B*58:01 and allopurinol-induced DRESS and MPE in this population. Therefore, HLA-B*58:01 can be used as a pharmacogenetic marker for allopurinol-induced CADR including SJS-TEN, DRESS and MPE. These results suggest that screening for HLA-B*58:01 alleles in patients who will be treated with allopurinol would be clinically helpful in preventing the risk of developing CARD in a Thai patients. Summary Regardless of phenotype, this is the first pharmacogenetic study of allopurinol-induced CADR in patients of Thai ancestry. In this study we confirmed the association between HLA-B*58:01 and allopurinol-induced SJS-TEN, DRESS, and MPE in Thai population. Regarding to our findings, the pharmacogenetic interpretation could be generalized to drug hypersensitivity including DRESS, SJS-TEN, and MPE.en_US
dc.identifier.citationFrontiers in Pharmacology. Vol.7, No.JUL (2016)en_US
dc.identifier.doi10.3389/fphar.2016.00186en_US
dc.identifier.issn16639812en_US
dc.identifier.other2-s2.0-84981502021en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/41280
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84981502021&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleHLA-B*58:01 for allopurinol-induced cutaneous adverse drug reactions: Implication for clinical interpretation in Thailanden_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84981502021&origin=inwarden_US

Files

Collections